Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Saghir on Ribociclib Plus Endocrine Therapy in Premenopausal HR+/HER2-Negative Advanced Breast Cancer

June 23rd 2025

Nagi S. El-Saghir, MD, FACP, FASCO, discusses ribociclib plus endocrine therapy in premenopausal HR-positive breast cancer by liver metastases status.

Health Canada Approves Adjuvant Ribociclib for HR+/HER2– Early Breast Cancer

June 19th 2025

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Five Under 5: Top Oncology Videos for the Week of 6/8

June 15th 2025

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases

June 12th 2025

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

The Role of Liquid Biopsies in Precision Approaches for Breast Cancer Therapy

June 11th 2025

Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.

RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer

June 10th 2025

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

Elacestrant Displays Potential as Combination Backbone in ER+ Breast Cancer After CDK4/6 Inhibition

June 10th 2025

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

Five Under 5: Top Oncology Videos for the Week of 6/1

June 8th 2025

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

FDA Receives NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

June 6th 2025

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications

June 3rd 2025

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer

June 2nd 2025

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 2nd 2025

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

Sacituzumab Govitecan Plus Pembrolizumab Displays Activity in Early-Stage TNBC

June 1st 2025

Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.

Ribociclib Benefit Is Sustained in HR+ Early Breast Cancer Regardless of Age, Menopausal Status

June 1st 2025

Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.

Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer

June 1st 2025

Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.

Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer

May 31st 2025

Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.

Imlunestrant With/Without Abemaciclib Generates Improved PROs in ER+/HER2– Advanced Breast Cancer

May 31st 2025

Patient-reported outcomes revealed that imulunestrant with or without abemaciclib was favored vs SOC in ER-positive, HER2-negative breast cancer.

Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer

May 31st 2025

PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.

ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC

May 31st 2025

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.